DeepMed Research

BAVARIAN NORDIC

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: -

Established: 1992-01-01

Employees: 759

Market Cap: $3.1B

Website: http://www.bavarian-nordic.com

Clinical Trials

A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV Vaccine

Phase 2

Recruiting

Conditions: Encephalitis

Interventions: Biological: MVA-BN-WEV
Other: Placebo

First Posted Date: 2025-03-28

Last Posted Date: 2025-03-28

Lead Sponsor: Bavarian Nordic

Target Recruit Count: 400

Registration Number: NCT06899802

Locations: 🇺🇸
Benchmark Research, San Angelo, Texas, United States
🇺🇸
Lifeline Primary Care, Inc. / CCT Research, Lilburn, Georgia, United States
🇺🇸
Clay-Platte Family Medicine, P.C./CCT Research, Kansas City, Missouri, United States

and more 4 locations

Open-label, Multicenter Immunogenicity and Safety Study of MVA-BN Vaccine in Children from 2 Years to Less Than 12 Years of Age Compared to Adults for the Prevention of Smallpox, Mpox, and Related Orthopoxvirus Infections

Phase 2

Recruiting

Conditions: Monkeypox (Mpox)

Interventions: Drug: MVA-BN

First Posted Date: 2024-08-12

Last Posted Date: 2025-02-26

Lead Sponsor: Bavarian Nordic

Target Recruit Count: 460

Registration Number: NCT06549530

Locations: 🇨🇩
University of Kinshasa, Kinshasa, Congo, The Democratic Republic of the
🇺🇬
Uganda Virus Research Institute, Entebbe, Uganda
🇺🇬
Epicentre Mbarara Research Centre, Mbarara, Uganda

Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination

Phase 3

Active, not recruiting

Conditions: Chikungunya Virus Infection

Interventions: Biological: CHIKV VLP vaccine booster
Biological: Placebo booster

First Posted Date: 2023-08-23

Last Posted Date: 2025-04-03

Lead Sponsor: Bavarian Nordic

Target Recruit Count: 800

Registration Number: NCT06007183

Locations: 🇺🇸
Alliance for Multispecialty Research, LLC, Norfolk, Virginia, United States
🇺🇸
Optimal Research, LLC, Peoria, Illinois, United States
🇺🇸
Suncoast Research Associates, LLC, Miami, Florida, United States

and more 12 locations

Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults ≥65 Years

Phase 3

Completed

Conditions: Chikungunya Virus

Interventions: Biological: Placebo
Biological: CHIKV VLP/adjuvant

First Posted Date: 2022-04-27

Last Posted Date: 2024-12-13

Lead Sponsor: Bavarian Nordic

Target Recruit Count: 413

Registration Number: NCT05349617

Locations: 🇺🇸
Rochester Clinical Research, Inc., Rochester, New York, United States
🇺🇸
Global Clinical Research Professionals (GCP), Saint Petersburg, Florida, United States
🇺🇸
Panax Clinical Research, Miami Lakes, Florida, United States

and more 7 locations

ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2

Phase 3

Completed

Conditions: COVID-19 Disease

Interventions: Biological: Comirnaty
Biological: ABNCoV2

First Posted Date: 2022-04-14

Last Posted Date: 2025-02-24

Lead Sponsor: Bavarian Nordic

Target Recruit Count: 4205

Registration Number: NCT05329220

Locations: 🇺🇸
Accel Research Site - NeuroStudies.net, LLC, Decatur, Georgia, United States
🇺🇸
DM Clinical Research, Sugar Land, Texas, United States
🇺🇸
Meridian Clinical Research - Family Practice, Portsmouth, Virginia, United States

and more 44 locations

MVA-BN-RSV Vaccine Trial

Phase 3

Terminated

Conditions: Respiratory Syncytial Virus Infections

Interventions: Biological: MVA-BN-RSV vaccine
Biological: Tris Buffered Saline (TBS)

First Posted Date: 2022-02-14

Last Posted Date: 2024-10-31

Lead Sponsor: Bavarian Nordic

Target Recruit Count: 20419

Registration Number: NCT05238025

Locations: 🇺🇸
Optimus U Corporation, Miami, Florida, United States
🇺🇸
De La Cruz Research Center, LLC, Miami, Florida, United States
🇺🇸
Great Lakes Clinical Trials at Ravenswood Rheumatology, Chicago, Illinois, United States

and more 109 locations

ABNCoV2 Vaccine in SARS-CoV-2 (COVID-19) Seronegative and Seropositive Adult Subjects

Phase 2

Active, not recruiting

Conditions: COVID-19 Disease

Interventions: Biological: ABNCoV2 100ug
Biological: ABNCoV2 50ug

First Posted Date: 2021-10-14

Last Posted Date: 2022-10-24

Lead Sponsor: Bavarian Nordic

Target Recruit Count: 197

Registration Number: NCT05077267

Locations: 🇩🇪
Emovis GmbH, Berlin, Germany
🇩🇪
Velocity Clinical Research Hamburg, Hamburg, Germany

A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317

Phase 3

Completed

Conditions: Chikungunya Virus

Interventions: Biological: CHIKV VLP/adjuvant
Biological: Placebo

First Posted Date: 2021-10-08

Last Posted Date: 2023-12-14

Lead Sponsor: Bavarian Nordic

Target Recruit Count: 3258

Registration Number: NCT05072080

Locations: 🇺🇸
Texas Center for Drug Development, Inc., Houston, Texas, United States
🇺🇸
Alliance for Multispecialty Research - Wichita East, Wichita, Kansas, United States
🇺🇸
Johnson County ClinTrials, Lenexa, Kansas, United States

and more 33 locations

A Study to Assess the Safety and Immunogenicity of PXVX0317 Chikungunya Virus Virus-Like Particle Vaccine

Phase 2

Completed

Conditions: Chikungunya Virus

Interventions: Biological: CHIKV VLP, adjuvanted

First Posted Date: 2021-10-04

Last Posted Date: 2023-07-03

Lead Sponsor: Bavarian Nordic

Target Recruit Count: 25

Registration Number: NCT05065983

Locations: 🇺🇸
Johnson County ClinTrials, Lenexa, Kansas, United States

Phase 2a Study of MVA-BN-RSV Vaccination and RSV Challenge in Healthy Adults

Phase 2

Completed

Conditions: RSV Infection

Interventions: Biological: MVA-mBN294B
Drug: Placebo

First Posted Date: 2021-02-12

Last Posted Date: 2023-07-21

Lead Sponsor: Bavarian Nordic

Target Recruit Count: 73

Registration Number: NCT04752644

Locations: 🇬🇧
hVIVO Services Limited, London, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy